Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Free Cash Flow (2016 - 2025)

Aethlon Medical (AEMD) has disclosed Free Cash Flow for 15 consecutive years, with -$1.7 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Free Cash Flow rose 35.01% year-over-year to -$1.7 million, compared with a TTM value of -$7.6 million through Mar 2025, up 26.35%, and an annual FY2025 reading of -$7.6 million, up 26.35% over the prior year.
  • Free Cash Flow was -$1.7 million for Q1 2025 at Aethlon Medical, up from -$2.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$1.7 million in Q1 2025 and bottomed at -$3.6 million in Q3 2022.
  • Average Free Cash Flow over 5 years is -$2.5 million, with a median of -$2.4 million recorded in 2023.
  • The sharpest move saw Free Cash Flow crashed 88.55% in 2022, then soared 35.58% in 2024.
  • Year by year, Free Cash Flow stood at -$2.8 million in 2021, then grew by 24.26% to -$2.1 million in 2022, then dropped by 13.51% to -$2.4 million in 2023, then rose by 15.66% to -$2.0 million in 2024, then rose by 17.02% to -$1.7 million in 2025.
  • Business Quant data shows Free Cash Flow for AEMD at -$1.7 million in Q1 2025, -$2.0 million in Q4 2024, and -$2.2 million in Q3 2024.